Savara initiates phase 2a clinical study of Molgradex for treatment of NTM lung infection
Savara announced initiation of a Phase 2a clinical study, OPTIMA, evaluating its lead product candidate Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor, for treatment of nontuberculous mycobacterial lung infection. March 13, 2018